STOCK TITAN

Recursion (NASDAQ: RXRX) director gets 88,424 RSUs, sells 3,963 shares

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

RECURSION PHARMACEUTICALS, INC. director Namandje Bumpus reported both an equity award and a small share sale. On June 17, 2026, Bumpus received a grant of 88,424 restricted stock units under the company’s Outside Director Compensation Policy. These units vest on the earlier of June 17, 2027 or the day before the 2027 annual stockholders’ meeting, subject to continued service.

On June 18, 2026, Bumpus sold 3,963 shares of Class A Common Stock in an open‑market transaction at $3.18 per share, executed under a Rule 10b5‑1 trading plan adopted on March 3, 2026. After the reported transactions, Bumpus directly owned 127,632 shares of Class A Common Stock.

Positive

  • None.

Negative

  • None.
Insider Bumpus Namandje
Role null
Sold 3,963 shs ($13K)
Type Security Shares Price Value
Sale Class A Common Stock 3,963 $3.18 $13K
Grant/Award Class A Common Stock 88,424 $0.00 --
Holdings After Transaction: Class A Common Stock — 127,632 shares (Direct, null)
Footnotes (1)
  1. Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026.
RSU grant size 88,424 shares Restricted stock units granted June 17, 2026
RSU vesting date June 17, 2027 Or day before 2027 annual meeting, service-based
Shares sold 3,963 shares Class A Common Stock sold June 18, 2026
Sale price $3.18 per share Open-market sale of Class A Common Stock
Post-transaction holdings 127,632 shares Class A Common Stock directly owned after transactions
RSU grant price $0.00 per unit Grant/award acquisition with no purchase price
Net share activity -3,963 shares Net buy/sell direction reported as net-sell
10b5-1 plan adoption date March 3, 2026 Covers the June 18, 2026 open-market sale
restricted stock units financial
"Represents a grant of restricted stock units automatically granted pursuant"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Outside Director Compensation Policy financial
"automatically granted pursuant to the Issuer's Outside Director Compensation Policy"
Rule 10b5-1 trading plan regulatory
"This transaction is pursuant to a Rule 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Class A Common Stock financial
"security_title": "Class A Common Stock""
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bumpus Namandje

(Last)(First)(Middle)
C/O RECURSION PHARMACEUTICALS
41 S. RIO GRANDE STREET

(Street)
SALT LAKE CITY UTAH 84101

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Common Stock06/17/2026A(1)88,424A$0131,595D
Class A Common Stock06/18/2026S(2)3,963D$3.18127,632D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.
2. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026.
Remarks:
/s/ Jonathan Golightly, attorney-in-fact06/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Namandje Bumpus report at Recursion (RXRX)?

Namandje Bumpus reported receiving 88,424 restricted stock units and selling 3,963 Class A shares. The award was a director grant, and the sale was an open‑market transaction executed under a pre‑arranged Rule 10b5‑1 trading plan.

How many Recursion (RXRX) shares did Namandje Bumpus sell and at what price?

Bumpus sold 3,963 shares of Recursion Class A Common Stock at $3.18 per share. The June 18, 2026 transaction was an open‑market sale made under a Rule 10b5‑1 trading plan adopted on March 3, 2026.

What equity award did Namandje Bumpus receive from Recursion (RXRX)?

Bumpus received a grant of 88,424 restricted stock units as an automatic award under Recursion’s Outside Director Compensation Policy. The units vest based on service, rather than purchase, and carry no cash exercise price per share.

When do Namandje Bumpus’s Recursion (RXRX) restricted stock units vest?

The 88,424 restricted stock units will vest on the earlier of June 17, 2027 or the day before Recursion’s 2027 annual meeting of stockholders. Vesting is contingent on Bumpus’s continued service to the company through that date.

How many Recursion (RXRX) shares does Namandje Bumpus hold after these transactions?

Following the reported grant and sale, Bumpus directly owned 127,632 shares of Recursion Class A Common Stock. This post‑transaction holding reflects the net position after receiving restricted stock units and selling 3,963 shares in the market.

Was Namandje Bumpus’s sale of Recursion (RXRX) shares pre-planned?

Yes. A footnote states the June 18, 2026 sale of 3,963 shares was executed under a Rule 10b5‑1 trading plan. That plan was adopted on March 3, 2026, indicating the disposition followed a pre‑arranged trading schedule.